FFAR2 and fatty liver disease: While sodium butyrate supplementation prevented this hepatic steatosis and injury, sodium butyrate supplementation did not ameliorate hepatic steatosis in the liver of GPR41−/− and GPR43−/− mice with HFFD diet (p < .001, Figure 5H,I).